No description available.

Removal of apoptotic cells by macrophages is required in order to prevent autoimmune responses. Previous studies have reported that group IIA secretory phospholipase A2 (sPLA2) preferentially binds to apoptotic cells and induces a chemotactic factor which promotes the migration of macrophages to apoptotic cells. Based on these observations, we hypothesized that the pool of sPLA2 trapped on apoptotic cells produces chemoattractant lipids that recruit macrophages to phagocytose the apoptotic cells. To test this hypothesis, Jurkat cells were cultured under normal conditions and induced to undergo early apoptosis through treatment with D,L-threo-dihydrosphingosine. Live and early apoptotic cells were incubated with catalytically active sPLA2 and then cell-associated catalytic activity was assessed. In contrast to previous reports, we observed no difference in the ability of live or early apoptotic cells to trap group IIA sPLA2 on their surfaces. However, transmigration assays involving THP-1 monocytes confirmed that the cell-bound pool of sPLA2 generates chemoattractants when bound to the surfaces of live cells. Surprisingly, sPLA2 does not have to be catalytically active to attract THP-1 monocytes. The treatment of live Jurkat cells with heparinase showed a marked reduction in the ability of sPLA2 to bind to live cells and exert catalytic activity, suggesting heparan sulfate proteoglycans are possibly receptors for sPLA2. Future experiments are being planned to identify sPLA2 receptor(s) on THP-1 monocytes.

Bag-1 Defizienz in Mäusen führt in der embryonalen Entwicklung zu einem lethalen Phänotyp mit schweren Defekten in Nervensystem und Leber. Neben der Expression der Inhibitor of Apoptosis Proteinen (IAP), ist ein Komplex aus Akt, Hsp70, Bag-1 und B-Raf für die Phosphorylierung eines spezifischen AS-Restes des pro-apoptotischen Proteins Bad für das Überleben wichtig (Gotz und Wiese et al., 2005). Das Ziel dieser Arbeit bestand darin, die Funktionen der Maus Bag-1 Isoformen in der neuronalen Entwicklung anhand von in vitro Modellen näher zu charakterisieren. Überexpression von Bag-1S und Bag-1L in PC12 Zellen zeigte, dass Bag-1S im Zytoplasma und im Zellkern exprimiert wird, Bag-1L nur im Zellkern. Eine eingeführte Punktmutation, die die Interaktion mit Hsp70 verhindert, führte zu einer zytoplasmatischen Expression von Bag-1Sm. Die Mutante Bag-1Lm blieb nukleär lokalisiert. Überexpression von Bag-1S führte zu einer Reduktion der Neuritenlänge. Bag-1L und die mutanten Isoformen zeigten diesen Effekt nicht. Der inhibierende Einfluss von Bag-1S auf das Neuritenwachstum ist bislang spekulativ. Die Regulation erfolgt vermutlich über den Komplex Bag-1, Hsp70, Akt und B-Raf. Die Analyse von Bag-1 - /- Neuralen Stammzellen zeigte im Vergleich zu Bag-1 +/+ Neuralen Stammzellen eine erhöhte Apoptose. Wurde durch Vireninfektion Bag-1S oder Bag-1L zurück in die Zellen gebracht, waren diese wieder in der Lage zu überleben. Die Mutanten zeigten diese Effekte nicht, so dass Hsp70 ein notwendiger Interaktionspartner für die überlebensfördernde Wirkung von Bag-1 ist. Bag-1 -/- Neurale Stammzellen zeigten außerdem gliale Differenzierungsdefekte, die nicht durch eine Rückführung der Isoformen gerettet werden konnten. Zusätzliche Experimente, die Neurale Stammzellen gezielt in die gliale Differenzierung durch Gabe von CNTF oder LIF leiten, zeigten, dass Bag-1 -/- Neurale Stammzellen durchaus in der Lage sind, gliale Zellen zu bilden. Bag-1 gilt auch als Modulator nukleärer Rezeptoren, wie dem Glucocorticoid-Rezeptor (GR). Die Kotransfektion der Bag-1 Isoformen mit GR-GFP, zeigte Änderungen des Expressionsmusters bei Bag-1L und Bag-1Lm, jedoch nicht bei Bag-1S und Bag-1Sm. Die Etablierung einer Methode zur in vivo Analyse von Glucocorticoid-Signalwegen in der Neuroneogenese von adulten Mäusen, war in ihren ersten Ansätzen erfolgreich, so dass diese nach einigen Optimierungen für weitere Analysen genutzt werden kann. / Missing Bag-1 leads to a lethal phenotype with strong defects in the nervous system and in the liver during mouse embryonic development. Besides the expression of inhibitor of apoptosis proteins (IAP), a complex of Bag-1, Akt, Hsp70 and B-Raf is important for the phosphorylation of a specific aa-residue of the pro-apoptotic protein Bad to support survival (Gotz und Wiese et al., 2005). The aim of this work was to analyse the functions of the mouse Bag-1 isoforms during neuronal development with in vitro models. The overexpression of Bag-1S and Bag-1L in PC12 cells showed that Bag-1S is localized in the cytoplasm and in the nucleus, Bag-1L only in the nucleus. A specific pointmutation, that is inhibiting the interaction with Hsp70, lead to a change in subcellular localisation. Bag-1Sm was predominantly expressed in the cytoplasm. The mutant Bag-1Lm showed no change in localization compared with Bag-1L. The overexpression of Bag-1S also lead to a strong reduced neurite length. Bag-1L and the mutant isoforms did not show this defect. Analysis of the signalling pathways including Akt and MAPK did not lead to a conclusive explanation. So the reason why Bag-1S reduces neurite growth remains speculative. Analysing Bag-1 -/- neural stem cells showed an increase in apoptosis as expected when compared to Bag-1 +/+ neural stem cells. Bringing back Bag-1S and Bag-1L in the cells by viral infection they were able to survive again. The mutants did not show the rescue effect, telling that the interaction with Hsp70 is necessary for survival effects of Bag-1 in neural stem cells. Bag-1 -/- neural stem cells also showed glial differentiation defects which could not not be rescued by the Bag-1 isoforms. Additional experiments forcing neural stem cells into the glial lineage by application of CNTF or LIF showed that Bag-1 -/- neural stem cells were able to differentiate into glial cells. Bag-1 is also known as a modulator of nuclear receptors, like the glucocorticoid receptor (GR). Cotransfection of the Bag-1 isoforms with GR-GFP lead to a change in expression pattern of Bag-1L and Bag-1Lm but not Bag-1S and Bag-1Sm. The establishment of an in vivo method for analysing the effects of glucocorticoid signalling pathways in neurogenesis in adult mice was successful and can be used after some more optimizing for further analysing.

In this study, murine ES cells and DT40 B cells were used in parallel to disrupt the Nfatc1 gene and to study the function of individual 6 Nfatc1 isoforms, especially the function of highly inducible NFATc1/aA.We found that the short isoform NFATc1/aA protects DT40 B cells against apoptosis while the long isoform NFATc1/aC appears to enforce apoptosis. DNA microarray studies have shown that in NFATc1" DT40 B cells expressing ectopically human NFATc1/aA, the pkc-theta gene is several fold stronger expressed as in wild type cells. Our results of EMSA (Electrophoretic Mobility Shift Assays) and ChIP (chromatin immuno-precipitation) experiments demonstrated the binding of NFATc1/aA to the pkc-theta promoter in vitro and in vivo. NF-kappa B was also found to bind to the NFATc1 P1-promoter in vitro and in vivo. These data suggest and further prove that NF-kappa B contributes to the induction of the NFATc1 P1 promoter upon activation of T cells. So, NFATc1/aA and NF-kappa B were found to cross-talk in the transcriptional upregulation of their target genes, such as the IL-2 gene and the Nfatc1 gene itself, at multiple steps upon induction of apoptosis. While the pro-apoptotic mechanism of NFATc1s long isoform(s) remains unclear, its corresponding “death partners” are worth further studies. The elucidation of functional roles of NFATc1s short or long isoforms in the control of apoptosis of lymphocytes helps to understand apoptosis regulation, and thereby, the fate of lymphocytes. / In der vorliegenden Studie wurden ES Zellen von der Maus und DT40 B Zellen vom Huhn verwendet, um paralell das Nfatc1 auszuknocken und die Rolle der einzelnen 6 Nfatc1 Isoformen zu studieren, insbesorndere die Funktion des stark induzierbaren NFATc1/aA.Wir konnten feststellen, daß die kurze Isoform NFATc1/aA" DT40 B Zellen gegen Apoptose schützt, während die lange Isoform NFATc1/aC scheinbar die Apoptose verstärkt. DNA Microarray Studien haben gezeigt, daß NFATc1-/-/aA DT40 B Zellen, die humanes NFATc1/aA ektopisch exprimieren, das pkc-theta Gen deutlich stärker exprimieren als in Wildtyp Zellen. Unsere Ergebnisse von EMSA und ChIP Experimenten demonstrieren die Bindung von NFATc1/aA an den pkc-theta Promoter in vitro und in vivo. Für NF-kappa B wurde eine Bindung am Nfatc1 P1 Promoter in vitro und in vivo gezeigt. Dies lässt vermuten, daß NF-kappa B eine Rolle bei der Induktion am Nfatc1 P1 Promoter nach der Aktivierung der T Zelle spielt.Es wurde herausgefunden, daß nach Induktion der Apoptose, NFATc1/aA und NF-kappa B „cross-talk“ an unterschiedlichen Stellen in der transkriptionellen Hochregulierung ihrer Zielgene, wie z.b. dem IL-2 Gen und dem Nfatc1 Gen selbst. Weil die pro-apoptotischen Mechanismen der lange(n) Isoform(en) von NFATc1 unklar bleiben, sollten die korrespondierenden „death partners“ in weiteren Studien untersucht werden. Eine Klärung der funktionellen Rollen der NFATc1 Isoformen in der Kontrolle der Apotose in Lymphozyten wird helfen,die Regulation der Apotose, und damit auch das Schicksal der Lymphozyten, zu verstehen.

Prionenerkrankungen oder Transmissible Spongiforme Enzephalopathien (TSEs) sind übertragbare Krankheiten, zu denen die Creutzfeldt-Jakob-Krankheit (CJD) beim Menschen, Scrapie bei Schafen und die Bovine Spongiforme Enzephalopathie (BSE) bei Rindern gehören. Der infektiöse Erreger (PrPSc) besteht dabei aus einer abnormalen Form des zellulären Prion-Proteins (PrPC) und unterscheidet sich von dieser nur in der Proteinstruktur. Ein Hauptproblem bei der Entwicklung von aktiven Immunisierungsstrategien gegen Prionenerkrankungen besteht in der fehlenden Reaktion des Immunsystems auf das ubiquitär exprimierte Selbst-Antigen PrPC, welche auf einer Immuntoleranz gegen das körpereigene Protein beruht. In dieser Arbeit wurde ein transgenes Mausmodell für aktive Immunisierungsexperimente verwendet. Diese transgenen Tiere exprimieren Hamster-PrPC (HaPrP) unter der Kontrolle des Neuronen-spezifischen Enolase-Promotors (NSE) ausschließlich im Nervensystem auf einem Prnpo/o-Hintergrund. Durch die Verwendung eines „artfremden“ Proteins (rekombinantes Maus-PrP) gegen endogenes Hamster-PrP als Vakzine sollte die Immunogenität des Proteins verstärkt werden. Zusätzlich wurde für die Immunisierungen ein Fusionsprotein aus Maus-PrP und einem T-Helferepitop des Tetanustoxins (P30) eingesetzt. Als Adjuvanz diente das bakterielle DNA-Motiv CpG-1826, welches die Fähigkeit besitzt T-und B-Lymphozyten direkt zu stimulieren und die Sekretion von Interleukinen zu induzieren. Die Immunisierungen erfolgten subkutan und wurden monatlich durchgeführt. Nach jedem Boost wurden die Blutseren auf Antikörper sowohl gegen Maus-PrP als auch gegen Hamster-PrP untersucht. Neben der Analyse der humoralen Immunantwort mittels ELISA, Westernblot und FACS, wurden die Seren der immunisierten Mäuse auf ihre Fähigkeit getestet, die Prionenreplikation in vitro zu inhibieren. Mit der gewählten Immunisierungsstrategie war es mit beiden Proteinen möglich, hohe Antikörperantworten sowohl gegen Maus- als auch gegen Hamster-Prion-Protein zu induzieren. In Zellkultur waren die Seren in der Lage, signifikant den PrPSc-Gehalt zu reduzieren. Die immunisierten Mäuse wurden mit Hamsterprionen infiziert, um den Einfluss der induzierten Antikörper auf den Verlauf der Krankheit zu untersuchen. Nach Immunisierung mit PrP-P30 zeigten die Mäuse gegenüber mit Ovalbumin-behandelten Kontrolltiere eine signifikant verlängerte Inkubationszeit von ca. 30%. Im Gegensatz dazu konnte nach Immunisierung mit PrP ohne das zusätzliche T-Helferepitop keine Verlängerung in den Inkubationszeiten beobachtet werden. Abschließend wurde die Immunantwort in den immunisierten Tieren auf zellulärer Ebene mittels Proliferationsanalyse von T-und B-Lymphozyten untersucht. Dafür wurden Lymphozyten aus Milz und Lymphknoten der immunisierten NSEHa-Prnpo/o_Mäusen isoliert, ex vivo mit Maus-PrP bzw. Hamster-PrP stimuliert und auf die Proliferation von CD4-positiven oder CD8-positiven T-Lymphozyten untersucht. Durch die Analyse wurde gezeigt, dass es nach Immunisierung mit rek.PrP oder PrP-P30 zu keiner spezifischen Proliferation von T-Lymphozyten kam. Die beobachtete humorale Immunantwort scheint also unabhängig von einer spezifischen T-Zell-Immunantwort zu wirken. Die vorliegenden Ergebnisse zeigen, dass es möglich ist, durch die Wahl von geeigneten Immunisierungsstrategien, die Toleranz gegen das Selbstprotein PrP zu brechen. Sie stellen eine Grundlage für weitere Forschungsansätze dar, um prophylaktische Immunisierungen gegen Prionenerkrankungen in Zukunft zu realisieren. In einem weiteren Teil der Arbeit wurde die Funktion der apoptotischen Faktoren BAX und BCL-2 in der Prionen-induzierten Neurodegeneration in vivo untersucht. Dazu wurde neuroektodermales Gewebe aus BAX-/- und BCL-2-/- -Embryonen in das Gehirn von PrP-Knockout-Mäusen (Prnpo/o) transplantiert. Diese PrPC-defizienten Tiere sind nicht mit Prionen infizierbar und können PrPSc nicht propagieren. Nach Langzeitinfektion mit Mausprionen wurden die Transplantate histochemisch auf Prionenpathologie untersucht. Die typischen neuropathologischen Veränderungen waren dabei strikt auf das PrPC-positive Transplantat begrenzt. Zusätzlich wurden die Transplantate auf apoptotische Veränderungen untersucht und dabei TUNEL-Färbungen und aktivierte-Caspase-3 Färbungen durchgeführt. Es zeigten sich hierbei hinsichtlich Ausprägung und Stärke der Pathologie keine Unterschiede zwischen den BAX-bzw. BCL-2-Knockout Transplantaten und wildtypischen Transplantaten. Daraus konnte gefolgert werden, dass in diesem Modell weder BAX noch BCL-2 eine signifikante Rolle bei der Prionenpathogenese spielen. Die Ergebnisse aus diesem Teil der Arbeit leisten einen wichtigen Beitrag für das bessere Verständnis der durch Prionen-induzierten Neurodegeneration und sind für die Entwicklung von potentiellen therapeutischen Strategien hilfreich. / Transmissible spongiform encephalopathies (TSEs) are a group of fatal neurodegenerative disorders that affect animals as well as humans (Prusiner, 1997). The most prominent are Creutzfeldt-Jacob disease (CJD) in humans, bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep and goats and chronic wasting disease (CWD) in cervids. These diseases are characterized by the conversion of the cellular prion protein (PrPC) into the abnormally folded isoform termed PrPSc, which accumulates and represents the major component of infectious prions (Aguzzi and Polymenidou, 2004). The development of an effective PrP vaccine has been hampered by immunotolerance to the ubiquitously expressed endogenous PrPC and the immunization with recombinant PrP led only to weak antibody-responses against the protein in wildtype mice. Here, we tried to circumvent this problem experimentally by generation of anti-PrP immunity in hamster transgenic mice. These mice (NSEHa-Prnpo/o) express Hamster-PrP under the control of the neuron-specific enolase Promotor (NSE) exclusively in the nervous system on a Prnpo/o background (Race et al., 1995). To further enhance the immunogenic feature of the mouse Prion-Protein, we fused a T-Helper epitope of the tetanus toxin (P30) to the C-terminal end of the protein (Panina-Bordignon et al., 1989). This epitope has been successfully in the development of several anti-tumour vaccines (Hertz et al., 2001; Steinaa et al., 2008). For the immunization the recombinant mouse Prion-Protein (PrP) as well as the fusion construct, called PrP-P30, was used. The bacterial DNA-Motif CpG-1826 was co-injected as an adjuvant, known as a direct stimulator of T-and B-cells and to have the ability to induce the secretion of interleukins (Krieg, 2002). The immunization was performed monthly and the sera were analysed after every boost for the presence of antibodies against Mouse- and Hamster-PrP. Beside the analysis of the humoral response via ELISA, Westernblot and FACS, the sera of the immunized mice were tested for their ability to inhibit prion replication in vitro. With the selected immunization strategy it was possible to induce a high antibody response both against Mouse-PrP as well as against Hamster-PrP. In the cell culture assay with prion-infected cells a significant decrease of the PrPSc level was observed. Furthermore the immunized animals were inoculated with Hamster prions to assess the efficiency of the induced antibodies to prolong the incubation time of the disease. With the introduction of the T-Helper epitope P30 it was possible to prolong the survival time of the treated animals about 30%, in comparison to the animals receiving only PrP without P30 or control animals, which were treated with Ovalbumin, respectively. A second group of transgenic mice was immunized to investigate the cellular immune response by proliferation assays. Towards this, lymphocytes of spleen and lymph nodes of the immunized animals were isolated and stimulated ex vivo with either mouse- or hamster-PrP. This analysis showed that the induced humoral immune response was independent of T-cells, because no specific proliferation of neither CD4- nor CD8-positive T-cells could be observed. In conclusion, the results clearly demonstrate that the possibility to break the self-tolerance against PrP by using appropriate vaccination strategies. It therefore might open a new avenue for the future development of prophylactic prion vaccines. In a second part of the work, the role of BAX and BCL-2 in prion-mediated neurodegeneration was characterized in vivo. BAX- and BCL-2- deficient neuroectodermal tissue was transplanted into the brain of Prnpo/o recipient mice. Mice devoid of PrPC (Prnpo/o) are resistant to prions and do not propagate the infectious agent (Bueler et al., 1993). After long-term infection with mouse scrapie prions, typical histopathological features of the disease, such as gliosis, spongiosis and PrPSc accumulation were examined with histochemical techniques in the engrafted brains and the pathological changes were restricted to the PrPC-expressing neurografts. Furthermore we perform TUNEL and active-Caspase 3 stainings for determination and detection of apoptotic changes in the neurografts. Regarding the strength and characteristics of prion pathology no differences were seen between BAX- and BCL-2-Knockout grafts in comparison to the wildtype tissue. In summary, these results demonstrate that neither BAX nor BCL-2, two major players of apoptosis, are necessary for prion-induced neurodegeneration. These results therefore contribute to a better understanding of the pathogenic mechanisms in prion diseases and are useful for the development of future therapeutical strategies.

Thesis advisor: Jianmin Gao / My graduate research has used engineered peptides to perturb the non-covalent interactions in protein folding, protein-protein association and protein-membrane association. We have focused on understanding the fundamental principles of molecular recognition behind protein-protein and protein-membrane interactions, and further using these principles in protein engineering. This thesis includes three projects. I) Towards Small Molecule Receptors for Membrane Lipids: A Case Study on Phosphatidylserine The lipid composition and distribution of cell membranes play important roles in regulating the physiology of the cell. The lipid composition of plasma membranes is one characteristic feature that can be used to identify cell types and functions. Molecules that specifically recognize a particular lipid are useful as imaging probes for targeting cells or tissues of interest. Protein based lipid binding probes have intrinsic limitations due to their large size and poor pharmacokinetic properties such as slow clearance rate and poor in vivo stability. A plausible strategy to achieve a probe with small size and high binding affinity and selectivity is to use a peptide to mimic the protein lipid-binding domains. As a case study, a cyclic peptide that specifically targets phosphatidylserine containing membranes has been developed. This cyclic peptide is potentially capable of imaging apoptosis in vivo, and the strategy of developing this cyclic peptide can be generalized to the design of peptide-based probes for other lipid species. My research has pointed out a challenging but feasible way to design a peptide that achieves specificity and affinity similar to lipid-binding proteins. (II) Study of Apoptotic Cell Membrane (ACM) Permeant Molecules Noninvasive imaging of apoptosis is highly desirable for the diagnosis of a variety of diseases, as well as for the early prognosis of anticancer treatments. One characteristic feature of apoptotic cells that has been targeted for developing specific biomarkers is enhanced membrane permeability compared to that of healthy cells. Several unrelated molecules that are capable of selectively penetrating the apoptotic cell membrane (ACM) have recently been reported. However, the origin of the altered ACM permeability is poorly understood, as is the scope of molecular structures that can permeate through the ACM. Herein, we report a systematic investigation on the altered ACM permeability. Our results show that simple modifications of commonly used dyes (e.g. fluorescein) afford specific entry into cells at the early stages of apoptosis. The ACM appears to be permeable to molecules of various functional groups and charge, but does discriminate against molecules of large size. The new findings reported here greatly expand the pool of small molecules for imaging cell death, thus facilitating the development of noninvasive imaging agents for apoptosis. (III) Study of Aromatic-Fluorinated Aromatic Interactions in Peptide Systems Therapeutic proteins have been through a remarkable expansion in the last two decades. A general problem that they are facing is poor stability. Protein engineering focuses on solving this problem by incorporating unnatural amino acids into protein sequences to purposefully modify protein structures. Fluorinated aliphatic amino acids have been demonstrated to be effective in stabilizing protein structures and functioning as recognition motifs. In contrast, fluorinated aromatic amino acids are less studied. We investigated the effect of perturbation of fluorination on aromatic residues on the stability of protein model systems, as well as the influence on protein-protein association behavior. The results of this study provided a fundamental understanding of aromatic interactions in protein systems, and guidelines for protein engineering with fluorinated aromatics for stabilizing protein structures or directing specific protein-protein interactions. / Thesis (PhD) — Boston College, 2012. / Submitted to: Boston College. Graduate School of Arts and Sciences. / Discipline: Chemistry.

Rhabdomyosarcoma (RMS) is a highly malignant form of pediatric cancer that originates from skeletal muscle cells. While the normal skeletal muscle cells are generated via a highly regulated process called myogenesis that depends on myogenic regulatory factors (MRFs), the RMS cells fail to differentiate as a result of impaired myogenesis due to abnormal MRF activity. We found that TCEA3 regulates myogenin (an essential MRF member) activity at the gene expression level. Our work showed that depletion of TCEA3 in normal myoblast cells results in an inhibition of differentiation and downregulation of MRFs. TCEA3 confers myogenic activity and results in differential recruitment of RNAPII to target promoters. While its role in ovarian cancer is well understood, its role in RMS is yet unclear. Thus, our work focused on investigating the role of TCEA3 in both the RMS subtypes, ARMS and ERMS. The results revealed that TCEA3 is downregulated in both the RMS subtypes, and further, its overexpression resulted in a decrease in migration and inhibition of anchorage-independent growth. It also is shown to induce apoptosis through intrinsic and extrinsic pathways. Additionally, we found that over expressing TCEA3 in RMS cells could sensitize these cells to chemotherapeutic drugs. Similar to TCEA3, TCEAL7 is downregulated in various types of cancers, including over 90% of ovarian epithelial cancers, and has shown tumor suppressing properties in ovarian cancers. Our work on RMS showed that TCEAL7 is highly deregulated in both of the immortal cell lines representing ARMS and ERMS, and highly expressed in the normal myoblast cells. Further, deletion of Tceal7 inhibits the proliferation of myoblasts suggesting that TCEAL7 is involved in promoting cell cycle progression in myoblast cells. Deletion of TCEAL7 also revealed a loss of MyHC expression upon differentiation and overexpression of TCEAL7 in RMS promotes differentiation in RMS cells. Additionally, the overexpression of TCEAL7 has led to a decrease in expression of the oncogene, Cyclin D1. Overall, the overexpression of TCEAL7 in RMS cell induces apoptosis and sensitizes cells to TRAIL induced cell apoptosis.

"Alzheimer’s disease (AD) is the most widespread neurodegenerative disorder, affecting approximately 20 million people worldwide. AD pathology is primarily characterized by the formation of extracellular amyloid plaques resulting from the aggregation of insoluble amyloid-beta 1-42 (A-beta), and neurofibrillary tangles (NFT’s) resulting from intracellular aggregation of hyperphosphorylated tau protein. The current FDA-approved AD treatments do not stop or reverse neurodegeneration, but only treat the symptoms by increasing acetylcholine neurotransmitter. Our laboratory is attempting to provide an additional therapeutic approach by using neurotrophic factors to block apoptosis or to restore neurons. We previously demonstrated that, in an in vitro model for AD, hEPN-1 neurotrophic factor mimetics can block synthetic A-beta-induced neuronal cell death when added to cultures, presumably by blocking caspase activation. In this thesis, we extended these findings to study the effect of A-beta and hEPN-1 on tau hyperphosphorylation (as measured by immunoblots with phospho-specific antibodies) and nuclear DNA fragmentation (as measured by TUNEL staining), both in vitro and in vivo in AD transgenic mice. We found that A-beta induces the hyperphosphorylation of tau in both mouse N2a and human SHSY neuronal cells, and that hEPN-1 may lower this phosphorylation in N2a cells. Furthermore, we discovered that hEPN-1 can reduce nuclear DNA fragmentation when added both simultaneously to A-beta and 3 and 6 hours post A-beta addition. Finally, in vivo hEPN-1 may lower both tau hyperphosphorylation and caspase-7 related protein (C7RP) in AD transgenic (Tg) mice. The overall results validate our in vitro AD model, show the efficacy of hEPN-1 at blocking A-beta-induced DNA fragmentation even when added post-insult, and show that hEPN-1 may work in an AD mouse model. However, more studies must be conducted to confirm these findings. "

No description available.

Neutrophils are a central component of the innate immune system, whose major role is to defend the host against invading microorganisms. As such they are integral players in the process of inflammation, the response of vascular tissues to injury. They are frequently the first immune cells recruited from the systemic circulation into a site of tissue injury or infection where they themselves play a key antimicrobial role. Direct killing of microbes can be accomplished by phagocytosis, degranulation, production of reactive oxygen species (ROS) or the release of DNA and antimicrobial peptides into the extracellular milieu (NETosis). In addition neutrophils orchestrate the recruitment and activation of other leucocytes, further contributing to host defence. The central importance of neutrophils in immunity is revealed by defects in either number or function leading to recurrent life threatening infection. However, as the toxic arsenal of neutrophil constituents lack specificity they can also be damaging to surrounding host tissues causing exacerbated inflammation. It is therefore essential that neutrophil function is tightly controlled to allow an appropriate response to be mounted against invading pathogens while simultaneously minimising host tissue injury. Therefore, once the inciting inflammatory insult has been successfully cleared or controlled it is imperative that these non-tissue resident specialised immune cells are rapidly ‘switched off’ or cleared to allow the return to homeostasis. This resolution phase of the inflammatory cascade is now recognised as an energy dependent, finely controlled endogenous process, the beginnings of which are activated at the onset of inflammation. One of the main aims of resolution is to ensure efficient clearance of leucocytes that are no longer necessary. It is likely that a major clearance route is by the highly regulated and energy dependent processes of neutrophil programmed cell death (apoptosis) with subsequent uptake and disposal of apoptotic neutrophils by tissue macrophages. This process of neutrophil apoptosis renders the neutrophils nonfunctional and preserves cell membrane integrity, thus preventing further release of histotoxic neutrophil-derived inflammatory mediators into the extracellular environment. Furthermore, the recognition, uptake and disposal of apoptotic neutrophils cause a dynamic change in the phagocytosing macrophage phenotype with alterations in inflammatory mediator production. The fundamental importance of neutrophil apoptosis and subsequent efferocytosis in inflammation resolution is highlighted by the pathological consequences of neutrophil necrosis or failed apoptotic cell clearance, which leads to enhanced tissue injury and autoimmunity. Acute lung infection (pneumonia) is a common and serious condition affecting both developed and developing countries; globally, childhood pneumonia is the leading cause of death in children aged less than 5 years and pneumonia is the most common fatal infection in the developed world. In over half of patients with community acquired pneumonia no causative organism is ever isolated suggesting that although the immune response has successfully controlled infection, continued uncontrolled neutrophilic inflammation in the lung continues to cause morbidity and mortality. Indeed, pneumonia frequently progresses to acute respiratory distress syndrome (ARDS), a devastating acute inflammatory condition of the lungs characterized by inflammatory cell recruitment and accumulation of protein rich oedema fluid leading to impaired lung function. ARDS affects 200,000 critically ill patients in the USA per year, and has a substantial mortality rate of up to 40%. Despite advances in intensive care treatment and antimicrobial therapy mortality from pneumonia has not fallen since the 1950s, and at present there are no specific therapies for infection-related lung inflammation or ARDS. Understanding the mechanism behind such uncontrolled, persisting inflammation, and the need for novel approaches to target infection related lung injury are therefore both urgent and essential. This thesis examines the potential of neutrophil apoptosis-inducing pharmacological agents as potential treatments for infection-associated lung inflammation. The primary agents used include a cyclin-dependent kinase inhibitor as well as plant-derived polyphenolic flavones. The ability of these compounds to induce human neutrophil apoptosis in vitro, the key importance of the intracellular neutrophil survival protein Mcl-1 in mediating this process, and the effect of targeting Mcl-1 in human macrophages is investigated. In addition, neutrophilic inflammation is modelled in zebrafish and mice with both sterile and bacterial-driven models of inflammation. A key role for Mcl-1 is delineated in vivo, with it acting as an endogenous controller of the innate immune response by influencing neutrophil apoptosis, but without effects on macrophage apoptosis or ability to phagocytose apoptotic cells. Driving neutrophil apoptosis by down-regulation of Mcl-1 accelerates resolution of inflammation in vivo. This therapeutic approach is also found to have indirect anti-bacterial effects in a model of E. Coli induced pneumonia, in stark contrast to established anti-inflammatory approaches which routinely cause immune paresis and life threatening infection. As such, targeting inflammatory cell apoptosis by changes in Mcl-1 offers a potential new therapeutic approach for the treatment of infection-associated inflammation.